AMGN Q3 2026 Earnings Analysis
Amgen reported Q3 revenues of $10.4B (+8% YoY), raised full-year guidance, and achieved three positive Phase III readouts including IMDELLTRA's landmark results in small cell lung cancer.
Key Metrics
Key Takeaways
- Six growth drivers now represent 70% of product sales and grew 27% YoY, with total Q3 revenues of $10.4B up 8%.
- IMDELLTRA achieves 21.1 months vs 12.7 months median survival in first-line small cell lung cancer Phase III trial.
- Company raised full-year 2026 revenue and EPS guidance, supported by strong commercial execution and R&D productivity.
Listen On
Available In
Transcript
// Full episode scriptWelcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex.
And I'm Jordan. Today we're digging into Amgen's third quarter 2026 results — and honestly, this one's packed with pipeline news.
It really is. But before we get into it, the standard note: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
Good, let's get into the numbers.
Amgen posted $10.4 billion in total revenue for Q3, up 8% year-over-year. And the headline stat from management: six key growth drivers — Repatha, EVENITY, TEZSPIRE, UPLIZNA, BLINCYTO, and IMDELLTRA — now make up over 70% of product sales, and together they grew 27%.
That's a meaningful shift in the revenue mix. It tells you Amgen isn't just leaning on legacy blockbusters anymore — it's a portfolio actually built around newer, faster-growing medicines. Seventeen products posted double-digit growth, and seventeen are now annualizing above a billion dollars each.
On profitability, non-GAAP operating margin came in at 47%, free cash flow was $3.7 billion, and R&D spending jumped 11% — they're clearly reinvesting aggressively.
And the market liked it — shares were up over 3% on the print. Amgen also raised full-year guidance: revenue now expected between $38.9 and $39.7 billion, and non-GAAP EPS between $22.90 and $23.70. That's a confident move with just one quarter left in the year.
Let's talk individual products, because there's a lot here. Repatha did $1.1 billion, up 37%, riding new cardiovascular outcomes data and updated treatment guidelines. EVENITY grew 39% to $751 million. TEZSPIRE was up 43% to $538 million.
And rare disease was a real standout — UPLIZNA sales were up 191% to $451 million. That's not a typo. Strong uptake in myasthenia gravis and really encouraging durability data in IgG4-related disease.
Now let's get to what I think was the big story of the call — IMDELLTRA in small cell lung cancer.
Yeah, this is the one that had analysts buzzing. Sales more than doubled year-over-year to $406 million, but the real news was the Phase III DeLLphi-305 data presented at ESMO. In first-line maintenance, IMDELLTRA plus Imfinzi showed a median overall survival of 21.1 months versus 12.7 months for Imfinzi alone.
Management described getting a standing ovation when that data was presented in Madrid. That's not something you hear often on an oncology readout.
And it's not just the efficacy — the monitoring burden is dropping too. Original label required 22 to 24 hours of monitoring for the first doses; that's now down to 6 to 8 hours, and in this newer study design, monitoring was as low as 1 to 2 hours. That could open the door to community oncology clinics actually administering this, not just big academic centers.
On the call, Murdo Gordon, the commercial chief, called it a potential "cornerstone therapy" for small cell lung cancer — and noted the first-line maintenance opportunity alone could address roughly 23,000 patients in the U.S.
Beyond IMDELLTRA, they also had positive Phase III results for TEZSPIRE in eosinophilic esophagitis and for dazodalibep in Sjögren's disease — a condition with zero approved disease-modifying therapies today. Three positive Phase III readouts in one quarter is a strong batting average for an R&D org.
There was good Q&A color too. On MariTide, Amgen's obesity candidate, CFO Thomas Dittrich — in his first call as CFO — confirmed they're sticking with about $2.6 billion in CapEx this year, partly to prepare manufacturing for a potential MariTide launch.
And when asked about tolerability, Chief Medical Officer Jay Bradner made an interesting point — even though MariTide is dosed monthly or less frequently, the side-effect duration doesn't stretch out the way you might expect. Symptoms, when they occur, tend to be short-lived, similar to weekly GLP-1 drugs.
There was also a notable exchange on M&A. An analyst essentially asked why Amgen hasn't been more aggressive given the wave of biopharma deal-making lately. CEO Bob Bradway pushed back gently, saying their business development approach remains disciplined and focused on their four core therapeutic areas — not chasing deals for the sake of activity.
That discipline shows up in the capital allocation too — they raised the dividend 6% to $2.52 per share and kept buybacks capped at $3 billion for the year. Steady, not flashy.
So stepping back — what does this all mean going forward?
I think the story here is diversification plus pipeline depth. Amgen isn't a one-or-two-drug company anymore — they've got six growth engines firing, a biosimilars business still growing double digits, and now potentially transformative data in lung cancer, asthma-adjacent disease, and autoimmune conditions. If IMDELLTRA's first-line data holds up through regulatory review, that could be a meaningful growth driver for years.
And MariTide remains the wildcard — Phase III enrollment is now complete on several studies, so 2027 could bring the data that really determines how big that opportunity gets.
Before we wrap — everything discussed is AI-generated analysis for educational purposes. Past performance doesn't guarantee future results. Please do your own due diligence.
Well said. Lots to watch heading into Q4 — guidance was raised, the pipeline delivered three Phase III wins in a single quarter, and IMDELLTRA could be entering a whole new chapter.
We'll be watching those regulatory filings and the MariTide data closely. Thanks for tuning in to Beta Finch.
Until next time, take care — and we'll see you at the next earnings call.